Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan 28;29(2):641-658.
doi: 10.3390/curroncol29020057.

ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date

Sébastien Gendarme  1   2 , Olivier Bylicki  3 , Christos Chouaid  1   2 , Florian Guisier  4   5
Affiliations
Review

ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date

Sébastien Gendarme et al. Curr Oncol. .

Abstract

The ROS-1 gene plays a major role in the oncogenesis of numerous tumors. ROS-1 rearrangement is found in 0.9-2.6% of non-small-cell lung cancers (NSCLCs), mostly lung adenocarcinomas, with a significantly higher rate of women, non-smokers, and a tendency to a younger age. It has been demonstrated that ROS-1 is a true oncogenic driver, and tyrosine kinase inhibitors (TKIs) targeting ROS-1 can block tumor growth and provide clinical benefit for the patient. Since 2016, crizotinib has been the first-line reference therapy, with two-thirds of the patients' tumors responding and progression-free survival lasting ~20 months. More recently developed are ROS-1-targeting TKIs that are active against resistance mechanisms appearing under crizotinib and have better brain penetration. This review summarizes current knowledge on ROS-1 rearrangement in NSCLCs, including the mechanisms responsible for ROS-1 oncogenicity, epidemiology of ROS-1-positive tumors, methods for detecting rearrangement, phenotypic, histological, and molecular characteristics, and their therapeutic management. Much of this work is devoted to resistance mechanisms and the development of promising new molecules.

Keywords: ROS-1 protein; lung cancers; non-small-cell lung cancer; protein tyrosine-kinase receptors.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. World Health Association WHO Fact Sheet on Cancer. [(accessed on 20 October 2018)]. Available online: https://www.who.int/news-room/fact-sheets/detail/cancer.
    1. Shaw A.T., Ou S.-H.I., Bang Y.-J., Camidge D.R., Solomon B.J., Salgia R., Riely G.J., Varella-Garcia M., Shapiro G.I., Costa D.B., et al. Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer. N. Engl. J. Med. 2014;371:1963–1971. doi: 10.1056/NEJMoa1406766. - DOI - PMC - PubMed
    1. U.S. Food and Drug Administration FDA Approves Crizotinib Capsules. [(accessed on 17 November 2021)]; Available online: https://www.fda.gov/drugs/resourcesi-nformation-approved-drugs/fda-appro....
    1. European Medicines Agency Xalkori, INN-Crizotinib. [(accessed on 17 November 2021)]. Available online: https://www.ema.europa.eu/en/documents/product-information/xalkori-epar-....
    1. D’Angelo A., Sobhani N., Chapman R., Bagby S., Bortoletti C., Traversini M., Ferrari K., Voltolini L., Darlow J., Roviello G. Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies. Cancers. 2020;12:3293. doi: 10.3390/cancers12113293. - DOI - PMC - PubMed

MeSH terms

Substances